27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biogen Inc. (NASDAQ:BIIB) shares are trading higher after the company was granted accelerated FDA approval for its ADUHELM Alzheimer's candidate.
The accelerated approval has been granted based on data from clinical trials demonstrating the effect of ADUHELM on reducing amyloid beta plaques, a biomarker that is reasonably likely to predict clinical benefit, in this case a reduction in clinical decline, said in the company's press release.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The company reported 'In clinical trials, ADUHELM reduced amyloid beta plaques by 59%-71% at 18 months of treatment.'
Biogen discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases.
Biogen's stock was trading about 43% higher at $408.24 at the time of publication. The stock has a 52-week high of $468.55 and a 52-week low of $223.25.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.